CD38: A Potential Therapeutic Target in Cardiovascular Disease

Wanyun Zuo,Na Liu,Yunhong Zeng,Yaozhong Liu,Biao Li,Keke Wu,Yunbin Xiao,Qiming Liu
DOI: https://doi.org/10.1007/s10557-020-07007-8
2020-01-01
Cardiovascular Drugs and Therapy
Abstract:Substantial research has demonstrated the association between cardiovascular disease and the dysregulation of intracellular calcium, ageing, reduction in nicotinamide adenine dinucleotide NAD+ content, and decrease in sirtuin activity. CD38, which comprises the soluble type, type II, and type III, is the main NADase in mammals. This molecule catalyses the production of cyclic adenosine diphosphate ribose (cADPR), nicotinic acid adenine dinucleotide phosphate (NAADP), and adenosine diphosphate ribose (ADPR), which stimulate the release of Ca 2+ , accompanied by NAD+ consumption and decreased sirtuin activity. Therefore, the relationship between cardiovascular disease and CD38 has been attracting increased attention. In this review, we summarize the structure, regulation, function, targeted drug development, and current research on CD38 in the cardiac context. More importantly, we provide original views about the as yet elusive mechanisms of CD38 action in certain cardiovascular disease models. Based on our review, we predict that CD38 may serve as a novel therapeutic target in cardiovascular disease in the future.
What problem does this paper attempt to address?